摘要
目的观察莫沙必利与多潘立酮治疗功能性消化不良(FD)的临床差异,探讨莫沙必利治疗FD的临床疗效及安全性。方法 90例FD患者随机分为治疗组和对照组,每组45例。治疗组给予莫沙必利片治疗,对照组给予多潘立酮片治疗。治疗前后对患者的临床症状进行评价,观察并记录两组用药后的临床疗效以及治疗后1、3、6个月的累计复发率。结果治疗组治疗7、14 d的总有效率高于对照组(P<0.05);治疗组和对照组在1、3个月复发率方面比较,差异无统计学意义(P>0.05),在6个月后,治疗组累计复发率低于对照组,两组比较差异具有统计学意义(P<0.05)。结论莫沙必利治疗功能性消化不良的临床效果总体上优于多潘立酮,并可显著改善患者临床症状,不良反应少,值得临床推广使用。
ObjectiveTo observe the clinical difference between mosapride and domperidone in the treatment of functional dyspepsia （FD）, and to investigate the clinical effect and safety of mosapride in treating FD.MethodsA total of 90 FD patients were randomly divided into treatment group and control group, with 45 cases in each group. The treatment group received oral administration of mosapride tablets for treatment, while the control group received domperidone tablets. Evaluation of clinical symptoms was made before and after treatment, and records were made on the clinical effects and cumulative relapse rates in 1, 3, 6 months after treatment in the two groups.ResultsThe treatment group had higher total effective rate in 7 and 14 d of treatment than the control group （P〈0.05）. There was no statistically significant difference of relapse rate in 1 and 3 months between the treatment group and control group （P〉0.05）. After 6 months, the treatment group had lower relapse rate than the control group, and the difference between the two groups had statistical significance （P〈0.05）.ConclusionMosapride provides better clinical effect than domperidone in treating functional dyspepsia, and it can remarkably improve patients’ clinical symptoms with few adverse reactions. It is worthy of clinical promotion and application.
出处
《中国实用医药》
2015年第10期23-24,共2页
China Practical Medicine
